Background. Omadacycline (OMC) is a broad spectrum aminomethylcycline antibacterial in late stage clinical development (PO and IV formulations) for treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). OMC has potent in vitro activity against gram-positive (GP) pathogens expressing common resistance mechanisms to penicillins, tetracyclines, fluoroquinolones and macrolides.
In vitro Activity of Fosfomycin, Alone and Combined with Cefepime and
Background. Multi-drug resistant (MDR) gram-negative bacteria are serious clinical threats. Fosfomycin (FOF) is an epoxide antibiotic that causes bacterial cell death via disruption of cell wall synthesis. The addition of fosfomycin has been shown to restore susceptibility to other agents against MDR P. aeruginosa. We evaluated the in vitro activity of the new IV fosfomycin formulation, alone and combined with cefepime (FEP) and meropenem (MEM), against carbapenemase-producing Enterobacteriaceae.
Methods. 80 carbapenemase-producing isolates, including 31 metallo β-lactamase producing isolates (29 NDMs and 1 each IMP and VIM), 48 KPCs, and 1 OXA-48, were used. The in vitro susceptibility of FOF, FEP and MEM were tested by agar dilution with glucose-6 phosphate by CLSI methods. Combination testing was then performed against 25 representative isolates using fixed concentrations of FOF (8, 16, 32 , and 64 mg/mL) at 0.25X the MIC of FOF alone with doubling dilutions of FEP and MEM.
Results. Reduced activity was observed for FEP and MEM against the carbapenemase-producing isolates (Table) . 36.2% of the isolates were NDM1 and 60% were KPCs. A total of 92.5% of the isolates were resistant to either FEP or MEM. FOF plus MEM resulted in synergistic activity (4-fold reduction in MEM MIC at 0.25X FOF MIC) against 12 of 25 isolates used for combination testing, with no antagonism observed. For these 12 isolates, MEM MICs ranged from 2 to 16 mg/mL when combined with FOF vs. 16 to 128 mg/mL when tested alone. When combined with FEP, synergistic activity was also observed against 6 of the 25 isolates. However, antagonism was observed against 3 isolates with this combination.
Conclusion. The combination of FOF plus MEM resulted in synergistic activity against approximately half of the KPCs and metallo β-lactamase producing bacteria. Synergistic activity was observed less often with FOF plus FEP, although antagonism was uncommon. Further studies are warranted to determine the in vivo efficacy of FOF combinations. Results. Total resistance prevalence was < 5% for C/T (3.5%) and MEM (0%), vs. from 7.9% (TZP) to 59% (LVX) for other comparators (Table 1) . Resistance prevalence generally increased by resistance category from FQ-S through FQ-R to ESBL, and by clonal subgroup from non-H30 through H30 to H30Rx.
Conclusion. C/T is broadly active against E. coli clinical isolates from veterans, notwithstanding significant variation by resistance category and ST131-H30/H30Rx status; it outperformed all non-carbapenem comparators. C/T should prove useful as a carbapenem-sparing agent against multidrug-resistant E. coli ST131 infections. a P values shown where P < .05. NA, not applicable (no resistance). C/T MICs increased significantly (P < .001) along similar gradients as categorical resistance (Table 2) . 
